>

>

US quantitative market assessment: novel therapy for infectious disease

Service Areas
Therapeutic Areas

Other Therapeutic Areas

Client Type

Big Pharma

Client Problems

  • A top 50 global pharma company wanted to know how they could reach $500M US peak sales for a Phase 2/3 drug treating latent tuberculosis (LTBI)
     

  • The company also sought advice on how to re-frame the large and ill-defined literature prevalence to a more realistically addressable universe of patients, as well as identifying ways to grow that market

What We Did

  • Primary qualitative market research with 6 MD specialties (n=30) and payers (n=20)


     

  • Primary quantitative market research (conjoint design) with physicians across 6 specialties (n=350), and payers (n=50)


     

  • Market, revenue forecast, TPP assessment, and business case (NPV) analysis

Our Results And Insight

  • We illuminated the current market segments
     

  • Quantified MD demand in light of various product profile scenarios
     

  • Conjoint analyses with MDs and payers prioritized the key obstacles to uptake…
     

  • …and provided actionable steps to overcome those obstacles

See other case studies

Market Research case studies >

Other Therapeutic Areas case studies >

Service Areas Details

Market Research (Quantitive & Qualitative Study, TPP testing, Market Forecast Research)

Therapeutic Areas Details

Other Therapeutic Areas (Infectious Disease, Tuberculosis)

© 2019, First Principles Advisory Group. All Rights Reserved
SF Bay Area, Denver, Seattle, New York City, Cambridge
First Principles Advisory Group
1290 Howard Street Suite 323
Burlingame, CA 94010
(415) 669-5183
info@fpadvisory.net